推荐产品
质量水平
检测方案
≥98% (TLC)
形式
powder
颜色
white
溶解性
H2O: 50 mg/mL
创始人
Johnson & Johnson
SMILES字符串
Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2
InChI
1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H
InChI key
SWIJYDAEGSIQPZ-UHFFFAOYSA-N
基因信息
human ... CHRM1(1128) , CHRM2(1129) , CHRM3(1131) , CHRM4(1132) , CHRM5(1133)
正在寻找类似产品? 访问 产品对比指南
生化/生理作用
毒蕈碱型乙酰胆碱受体拮抗剂;可能通过下调生长促进基因,抑制膀胱平滑肌细胞的增殖。
特点和优势
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语:
Warning
危险声明
危险分类
Acute Tox. 4 Oral
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
dust mask type N95 (US), Eyeshields, Faceshields, Gloves
法规信息
新产品
International journal of clinical practice, 66(7), 663-670 (2012-06-16)
Standardised traditional outcome measures may fail to address factors that are important to patients and address irrelevant factors. Aim of this study was to assess patient-reported goals and goal achievement (GA) in the antimuscarinic treatment for overactive bladder (OAB) patients.
Adding to the evidence base: application drying time for oxybutynin chloride topical gel.
Urologic nursing, 32(5), 270-271 (2013-03-12)
Current medical research and opinion, 28(8), 1369-1379 (2012-07-10)
Evaluate patient and physician satisfaction with a novel formulation of a once-daily controlled-release (CR) oxybutynin (Uromax*) 15-mg tablet as both the initial and maintenance dose in elderly and non-elderly patients with overactive bladder (OAB). Patients not on anticholinergic treatment for
Annales francaises d'anesthesie et de reanimation, 31(7-8), 605-608 (2012-07-04)
Catheter-related bladder discomfort (CRBD) is an unrecognized clinical event. Symptoms of CRBD secondary to an indwelling urinary catheter mimic those of an overactive bladder, i.e. urinary frequency and urgency with or without urge incontinence. Stimulation of muscarinic receptors located in
Urologic nursing, 32(5), 265-269 (2013-03-12)
This study determined the median drying time for oxybutynin chloride topical gel (OTG) approved for treatment of overactive bladder was 3.1 minutes, Most participants reported positive perceptions of OTG attributes.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门